Controversies in Management of Portal Hypertension and Cirrhosis Complications in the Transplant Candidate

Similar documents
Management of Cirrhosis Related Complications

Ascites Management. Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology

Contraindications. Indications. Complications. Currently TIPS is considered second or third line therapy for:

Management of Ascites and Hepatorenal Syndrome. Florence Wong University of Toronto. June 4, /16/ Gore & Associates: Consultancy

NUTRITIONAL OPTIMIZATION IN PRE LIVER TRANSPLANT PATIENTS

VARICEAL BLEEDING. Ram Subramanian MD Hepatology & Critical Care Medical Director of Liver Transplant Emory University, Atlanta.

Management of Cirrhotic Complications Uncontrolled Ascites. Siwaporn Chainuvati, MD Siriraj Hospital Mahidol University

GI bleeding in chronic liver disease

The Management of Ascites & Hepatorenal Syndrome. Florence Wong University of Toronto. Falk Symposium March 14, 2008

ACG & AASLD Joint Clinical Guideline: Prevention and Management of Gastroesophageal Varices and Variceal Hemorrhage in Cirrhosis

Initial approach to ascites

Conflict of interest disclosures. Complications of end stage liver disease. None. The many complications of Cirrhosis. Portal Hypertension.

CLINICAL How Should a Hospitalized Patient with Newly Diagnosed Cirrhosis Be Evaluated and Managed?

Luis S. Marsano, MD Professor of Medicine Division of Gastroenterology, Hepatology and Nutrition University of Louisville and Louisville VAMC 2015

BETA-BLOCKERS IN CIRRHOSIS.PRO.

From Sodium Retention to Therapy for Refractory Ascites The Role for New Drugs. Florence Wong University of Toronto. Falk Symposium October 14, 2007

Evidence-Base Management of Esophageal and Gastric Varices

Primary Prophylaxis against Variceal Hemorrhage Pharmacotherapy vs Endoscopic Band Ligation

Esophageal Varices Beta-Blockers or Band Ligation. Cesar Yaghi MD Hotel-Dieu de France University Hospital Universite Saint Joseph

The Continuum of Care for Advanced Liver Disease: Partnering with the Liver Specialist. K V Speeg, MD, PhD UT Health San Antonio

Management of Portal Vein Thrombosis With and Without Cirrhosis

Assessment of Liver Function: Implications for HCC Treatment

EDUCATION PRACTICE. Management of Refractory Ascites. Clinical Scenario. The Problem

JOURNAL PRESENTATION. Dr Tina Fan Tseung Kwan O Hospital 17 th Jan 2013

Management of Acute Decompensation of Cirrhosis JOHN O GRADY KING S COLLEGE HOSPITAL

Learning Objectives. After attending this presentation, participants will be able to:

Liver Transplantation Evaluation: Objectives

Steps in Assessing Fibrosis 4/30/2015. Overview of Liver Disease Associated With HCV

Norepinephrine versus Terlipressin for the Treatment of Hepatorenal Syndrome

Hepatology on the AMU

Virtual Mentor American Medical Association Journal of Ethics December 2008, Volume 10, Number 12:

Case Report: Refractory variceal bleeding Christophe Hézode, Henri Mondor Hospital, Paris-Est University, Créteil, France

ESLD a Guide for HIV Physicians. Marion Peters University of California San Francisco June 2015

End-Stage Liver Disease (ESLD): A Guide for HIV Physicians

CIRRHOSIS Definition

Causes of Liver Disease in US

Managing Cirrhosis. Cirrhosis of the liver is a progressive, fibrosing. Ascites. By Cameron Ghent, MD, FRCPC. Complications of Cirrhosis

Beta-blockers in cirrhosis: Cons

Variceal bleeding. Mainz,

Manejo Actual del Sangrado por Varices Gástricas

Care of the Patient With Cirrhosis

PORTAL HYPERTENSION An Introduction to the Culprit of Many Liver Failure Complications

MANAGEMENT OF LIVER CIRRHOSIS: PRACTICE ESSENTIALS AND PATIENT SELF-MANAGEMENT

Hepatocellular Carcinoma: Diagnosis and Management

Cirrhosis Patient Teaching Information

HCV care after cure. This program is supported by educational grants from

Hepatorenal Syndrome

BRTO /PARTO Indications and outcomes

Hepatitis C: How sick can we treat? Robert S. Brown, Jr., MD, MPH Vice Chair, Transitions of Care Interim Chief, Division of

Hepatocellular Carcinoma (HCC)

Ammonia level at admission predicts in-hospital mortality for patients with alcoholic hepatitis

Chronic Hepatic Disease

Alcoholic Hepatitis: Routine Screening for Early Recognition and Management. Juan Guerrero, MD

CIRROSI E IPERTENSIONE PORTALE NELLA DONNA

Life After SVR for Cirrhotic HCV

Treating patients with end-stage liver disease: Are we ready? Dr. Mino R. Mitri, M.D., C.M., M.Ed., FRCPC

Minimizing Complications in Cirrhosis

Cognitive abnormalities in cirrhosis

Ontario s Adult Referral and Listing Criteria for Liver Transplantation

ESPEN Congress Madrid 2018

Nutrition in Liver Disease An overview of the EASL Clinical Practice Guidelines

Acute Liver Failure. Neil Shah, MD UNC School of Medicine High-Impact Hepatology Saturday, Dec 8 th, 2018

Use of transjugular intrahepatic portosystemic shunt in liver disease

Cirrhosis and Portal Hypertension Gastroenterology Teaching Project American Gastroenterological Association

Severity and Mortality Prediction in Chronic Liver Disease using Child PUGH and MELD scales

NCEPOD - Measuring the Units; A review of patients who died with alcohol-related liver disease

Update in abdominal Surgery in cirrhotic patients

Program Disclosure. This program is supported by an educational grant from Salix Pharmaceuticals.

following the last documented transfusion; thereafter, evaluate the residual impairment(s).

PREVALENCE OF NAFLD & NASH

Management of Chronic Liver Failure/Cirrhosis Complications in Hospitals. By: Dr. Kevin Dolehide

TIPS. D Patch Royal Free Hospital London UK

Portal Hypertensive Gastropathy and Gastric Antral Vascular Ectasia

FATTY LIVER DISEASE (NAFLD) (NASH) A GROWING

Michele Bettinelli RN CCRN Lahey Health and Medical Center

Complication of Portal Hypertension: should the patients in the waiting list be treated differently?

Diagnostic Procedures. Measurement of Hepatic venous pressure in management of cirrhosis. Clinician s opinion

Cirrhosis: Let s get moving!

On-Call Upper GI Bleeding. Upper Gastrointestinal Bleeding

Editorial Process: Submission:07/25/2018 Acceptance:10/19/2018

European. Young Hepatologists Workshop. Organized by : Quantification of fibrosis and cirrhosis outcomes

Upper gastrointestinal bleeding in children. Nguyễn Diệu Vinh, MD Department of Gastroenterology

Management of the Cirrhotic Patient in the ICU

Hemostasis and Thrombosis in Cirrhotic Patients

The Yellow Patient. Dr Chiradeep Raychaudhuri, Consultant Hepatologist, Hull University Teaching Hospitals NHS Trust

Supplemental Appendix. 1. Protocol Definition of Sustained Virologic Response. A patient has a sustained virologic response if:

Hepatitis C: New Antivirals in the Liver Transplant Setting. Maria Carlota Londoño Liver Unit Hospital Clínic Barcelona

Liver Transplantation: The End of the Road in Chronic Hepatitis C Infection

Decompensated chronic liver disease

King Abdul-Aziz University Hospital (KAUH) is a tertiary

Evaluating HIV Patient for Liver Transplantation. Marion G. Peters, MD Professor of Medicine University of California San Francisco USA

The MELD Score in Advanced Liver Disease: Association with Clinical Portal Hypertension and Mortality

Hepatology cases for the generalist. Will Gelson Consultant Hepatologist Addenbrooke s Hospital

LIVER CIRRHOSIS. The liver extracts nutrients from the blood and processes them for later use.

Clinical Trials & Endpoints in NASH Cirrhosis

The place of bariatric surgery in NASH: can we extend the indications? - No

JMSCR Vol 05 Issue 11 Page November 2017

Are we adequately screening at-risk patients for hepatocellular carcinoma in the outpatient setting?

Transcription:

Controversies in Management of Portal Hypertension and Cirrhosis Complications in the Transplant Candidate Patrick Northup, MD, FAASLD, FACG Medical Director, Liver Transplantation University of Virginia

Disclosures Financial: None Off label indications: None

Overview General Cirrhosis Considerations Malnutrition, sarcopenia, frailty Portal vein thrombosis Ascites and Edema HRS, beta-blocker use, midodrine, albumin infusions Variceal Bleeding When to TIPS Encephalopathy Dietary restriction, ammonia levels, minimal HE

Progression of Cirrhosis Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases, Volume: 65, Issue: 1, Pages: 310-335.

Sarcopenia, malnutrition, frailty

Sarcopenia, malnutrition, frailty

Sarcopenia in cirrhosis It s not just malnutrition, can happen in the morbidly obese Loss of skeletal muscle mass More typical in patients with severe ascites and edema Leads to poor functional status which is a strong predictor of transplant (and non-transplant) outcomes

Sarcopenia in cirrhosis after an overnight fast the caloric requirements of patients with alcoholic cirrhosis are normal, but the nature of fuels oxidized are similar to normal humans undergoing 2-3 d of total starvation. Thus, patients with alcoholic cirrhosis develop the catabolic state of starvation more rapidly than do normal humans Owen OE, et al, J Clin Invest 1983; 72(5): 1821-32.

Sarcopenia eventually leads to frailty

Sarcopenia and Liver Transplantation

Six minute walk is a good starting point

Six minute walk is a good starting point

How can we help with sarcopenia and frailty Prehabilitation, or increased muscle mass and activity level has shown benefit for liver transplant recipients Not clear whether this is a self fulfilling prophecy : those able to prehab might have done well anyway Developing data on BCAA enriched evening snack Reasonable to supplement with 300-400 kcal at 11 pm

Portal vein thrombosis Occlusive main trunk PVT Cavernoma

Importance of PVT: transplant survival 148 occlusive PVT 3147 no or non occlusive PVT Hazard ratio by Cox multiple regression analysis Englesbe Liver Transplant 2010;16:83-90

How to Treat: Anticoagulation, Low Molecular Weight Heparins Once varices are controlled, overall bleeding rates appear similar or modestly higher than noncirrhosis patients. Severe bleeding is rare. Adapted from Intagliata, et al, Clinical Liver Disease; 28 June 2016

How to Treat: Anticoagulation Direct-acting Oral Anticoagulants (DOAC) in Cirrhosis Patients Intagliata, et al, Dig Dis Sci 2016; 61: 1721-7

Pearls about PVT and Transplant Must rule out malignant thrombus, HCC spreads to the PV frequently Eradicate EV s as per practice guidelines before starting therapy Not an indication for hospital admission or ED visit if the patient is asymptomatic but should be treated within 6-8 weeks for best chance IR approaches have shown benefit but require a skilled hand and experience

Issues in ascites and edema management

Ascites management notes Remember, it s sodium balance that affects fluid balance, sodium restriction to less than 2000 mg daily is the key for fluid control Overall fluid restriction is not recommended unless sodium is less than 125 mmol/l Runyon, et al. Hepatology 2013; 57(4): 1651 Spironolactone monotherapy is superior to furosemide monotherapy, best when used together in proportional doses however Perez-Ayuso, et al. Gastroenterology 1983; 84:961-8

Midodrine for refractory ascites J Hepatol 2012; 56:348-354

Stop beta-blockers? When? Why? Hepatology 2010; 52(3): 1017-23

Stop beta-blockers? When? Why? The risks versus benefits of beta blockers must be carefully weighed in each patient with refractory ascites. Systemic hypotension often complicates their use. Consideration should be given to discontinuing or not initiating these drugs in this setting. (Class III, Level B) Hepatology 2010; 52(3): 1017-23

Albumin infusions for ascites? 20% albumin infusion 40 g twice weekly for 2 weeks and then once weekly thereafter for 18 months in patients with persistent ascites after failing to completely respond to high dose diuretics Lancet 2018 June; 391: 2417-29

Albumin infusions for ascites? Lancet 2018 June; 391: 2417-29

Terlipressin for HRS: Finally? Journal of Hepatology 200O; 33: 43-48

Variceal Bleeding

Early TIPS for EV bleeding? NEJM 2010; 362(25): 2370-79

Early TIPS for EV bleeding? The trial had many exclusion criteria, including CTP class A, CTP class B without active bleeding at endoscopy, CTP C patients with a score of 14 and 15 points, age > 75 years, HCC outside Milan criteria, a creatinine level greater than 3 mg/dl, previous combination pharmacological plus endoscopic treatment to prevent rebleeding, bleeding from isolated gastric or ectopic varices, total PVT, and heart failure. Patients included in the study constituted <20% of those admitted for VH. Notably, observational studies have not confirmed the effect of early TIPS on survival and further studies are necessary Garcia-Tsao, et al, Hepatology 2017; 65(1): 310-35

Hepatic Encephalopathy

Encephalopathy notes It s not all ammonia. In fact, ammonia is unlikely to be the sole pathogenic force in most HE HE level and activity have little to do with dietary protein intake in the vast majority of patients Sarcopenia and frailty are deadly consequences of advanced decompensated cirrhosis and dietary restriction may contribute to malnutrition and harm

Please stop following ammonia levels Patients without evidence of hepatic encephalopathy (grade 0) frequently had ammonia levels above 47 mmol/l, for example, 69% (20/29) of the patients without signs or symptoms of encephalopathy had total arterial ammonia levels greater than that threshold Ong, et al, Am J Medicine 2003;114:188-93 High blood-ammonia levels alone do not add any diagnostic, staging, or prognostic value in HE patients with CLD Vilstrup, et al, Hepatology 2014; 60(2): 715-735.

Minimal and Covert HE Subtle or often subclinical confusion or slowed mentation. Frequently noted only by the patient s family members. Diagnosis should not be made with ammonia testing Must be diagnosed with neuropsychological tests and psychometric tests and performed by experienced examiners Cannot be diagnosed in the setting of confounding factors Vilstrup, et al, Hepatology 2014; 60(2): 715-735.

It s generally a bad idea to restrict dietary protein and it has no effect on hepatic encephalopathy incidence or severity. Daily protein intake should be 1.2-1.5 g/kg/d Cordoba, et al, J Hepatol 2004; 41(1): 38-43.

Summary General Cirrhosis Considerations Malnutrition, sarcopenia, frailty are important Portal vein thrombosis can be treated Ascites and Edema beta-blocker use, midodrine, albumin infusions all may have an impact Variceal Bleeding Early TIPS might have a survival benefit for a some Encephalopathy Dietary restriction, ammonia levels should not be used Covert HE can be diagnosed with advanced testing

Thank you